"These results from the CDCO bolster the already well-developed case for advancing inhalational drug candidates through a development program, and have accelerated interest in advancing alternative candidates forward for oral treatment of assorted fibrotic conditions. The value for the research program is immense through allowing us to focus our future resources on the most promising compounds."

"The outcome of the screen is to demonstrate that tumours with over-active AURKA-PLK1 pathway are likely to be sensitive to drugs targeting replication stress, a class of drugs we have found to have highly effective anti-tumour activity and very little normal tissue toxicity"

“Kathleen has produced an exceptionally high quality screening project that has clear clinical implications. The project was delivered exactly as we had imagined, we added some advanced elements to the imaging and the analysis that were value-add technology applications that had evolved subsequent to the TIA application.”